NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Subjects United States. Food and Drug Administration. Remove constraint Subjects: United States. Food and Drug Administration. Dates by Range 2000 and later Remove constraint Dates by Range: 2000 and later

Search Results

2. 30-Day notices, 135-day premarket approval (PMA) supplements and 75-day humanitarian device exemption (HDE) supplements for manufacturing method or process changes: guidance for industry and Food and Drug Administration staff

7. The Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program: guidance for industry, accreditation bodies, testing laboratories, and Food and Drug Administration staff

8. Acne vulgaris: establishing effectiveness of drugs intended for treatment

9. Adaptive designs for clinical trials of drugs and biologics

10. Administrative procedures for CLIA categorization: guidance for industry and Food and Drug Administration staff

11. Advancement of emerging technology applications for pharmaceutical innovation and modernization

12. Allergic rhinitis: developing drug products for treatment

14. Amyotrophic lateral sclerosis: developing drugs for treatment

15. Anthrax: developing drugs for prophylaxis of inhalational anthrax

16. Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases

17. Antibiotics: FDA has encouraged development, but needs to clarify the role of draft guidance and develop qualified infectious disease product guidance : report to Congressional requesters

18. Appropriate use of voluntary consensus standards in premarket submissions for medical devices: guidance for industry and Food and Drug Administration staff

19. Assessing COVID-19-related symptoms in outpatient adult and adolescent subjects in clinical trials of drugs and biological products for COVID-19 prevention or treatment

21. Assessing user fees under the Prescription Drug User Fee Amendments of 2017

22. Assessing user fees under the biosimilar user fee amendments of 2017

23. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment

24. Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion

26. Basic safety and essential performance of medical electrical equipment, medical electrical systems, and laboratory medical equipment: standards specific information for the Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program : guidance for industry, accreditation bodies, testing laboratories, and Food and Drug Administration staff

27. Best practices for communication between IND sponsors and FDA during drug development: guidance for industry and review staff : good review practice

28. Bioanalytical method validation

29. Biocompatibility testing of medical devices: standards specific information for the Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program : guidance for industry, accreditation bodies, testing laboratories, and Food and Drug Administration staff

33. Breast implants: certain labeling recommendations to improve patient communication : guidance for industry and Food and Drug Administration staff

34. COVID-19 public health emergency: general considerations for pre-IND meeting requests for COVID-19 related drugs and biological products : guidance for industry and investigators

36. CT contrast media power injectors can rupture conventional IV sets

38. Cancer clinical trial eligibility criteria: minimum age considerations for inclusion of pediatric patients : guidance for industry and IRBs

39. Cancer clinical trial eligibility criteria: patients with HIV, hepatitis B Virus, or hepatitis C Virus Infections

40. Cancer clinical trial eligibility criteria: patients with organ dysfunction or prior or concurrent malignancies

42. Center for Devices and Radiological Health appeals processes: questions and answers about 517A : guidance for industry and Food and Drug Administration staff

43. Certificates of confidentiality: guidance for sponsors, sponsor-investigators, researchers, industry, and food and drug administration staff

45. Changes to existing medical software policies resulting from section 3060 of the 21st Century Cures Act: guidance for industry and Food and Drug Administration staff

46. Chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs)

48. Chronic hepatitis C virus infection: developing direct-acting antiviral drugs for treatment

49. Chronic obstructive pulmonary disease: use of the St. George's Respiratory Questionnaire as a PRO assessment tool

50. Citizen petitions and petitions for stay of action subject to section 505(q) of the Federal Food, Drug, and Cosmetic Act